solute carrier family 9 member 7 pseudogene 1Genealiases: []
Q-omics provides the consensus-scored SLC9A7P1 profile across patient tissues and cancer cell-line models. SLC9A7P1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SLC9A7P1 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, SLC9A7P1 RNA expression shows 18,122 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, KICH, and UVM as cancer lineages where SLC9A7P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC9A7P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC9A7P1 survival associations across molecular data types. SLC9A7P1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC9A7P1 RNA expression–survival associations across cancer types. High SLC9A7P1 expression shows unfavorable associations in LUSC, BLCA, STAD and UCEC, but favorable associations in ACC and HNSC. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SLC9A7P1 RNA expression.
This table summarizes SLC9A7P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for SLC9A7P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC9A7P1 shows lower tumor expression in KICH, BLCA, LUSC and BRCA and higher tumor expression in THCA and LIHC. The KICH box plot shows higher SLC9A7P1 RNA expression in normal versus tumor tissue (log2 FC = −1.330, t-test p < 0.001).
This table shows molecular features associated with SLC9A7P1 in patient tissues and cancer cell lines. In patient samples, SLC9A7P1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
